Literature DB >> 11290561

Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection.

J C Aliberti1, J T Souto, A P Marino, J Lannes-Vieira, M M Teixeira, J Farber, R T Gazzinelli, J S Silva.   

Abstract

Infection with Trypanosoma cruzi causes a strong inflammatory reaction at the inoculation site and, later, in the myocardium. The present study investigates the role of cytokines as modulators of T. cruzi-induced chemokine expression in vivo and in vitro. In macrophage cultures, although the stimulation with interferon (IFN)-gamma increases the expression of IP-10, it blocks KC expression. Tumor necrosis factor (TNF)-alpha, on the other hand, potentiates KC, IP-10, macrophage inflammatory protein-1alpha, and JE/monocyte chemotatic protein-1 expression. Interleukin-10 and transforming growth factor-beta inhibited almost all chemokines tested. The role of IFN-gamma and TNF-alpha in chemokine modulation during infection was investigated in T. cruzi-infected IFN-gamma-deficient (GKO) or TNF-R1/p55-deficient (p55-/-) mice. The expression of chemokines detected in the inoculation site correlated with the infiltrating cell type observed. Although GKO mice had a delayed and intense neutrophilic infiltrate correlating with the expression of KC and macrophage inflammatory protein-2, none of the above was observed in p55-/- mice. The detection of infiltrating T cells, Mig, and IP-10 in the myocardium was observed in wild-type and p55-/-, but not in GKO mice. Together, these results suggest that the regulatory roles of IFN-gamma and TNF-alpha on chemokine expression may play a crucial role in the modulation of the inflammatory response during T. cruzi infection and mediate resistance to infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290561      PMCID: PMC1891919          DOI: 10.1016/s0002-9440(10)64094-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells.

Authors:  J Aliberti; C Reis e Sousa; M Schito; S Hieny; T Wells; G B Huffnagle; A Sher
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

2.  IL-10 mediates susceptibility to Trypanosoma cruzi infection.

Authors:  S G Reed; C E Brownell; D M Russo; J S Silva; K H Grabstein; P J Morrissey
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

3.  Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice.

Authors:  F Torrico; H Heremans; M T Rivera; E Van Marck; A Billiau; Y Carlier
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

4.  IFN-gamma selectively inhibits lipopolysaccharide-inducible JE/monocyte chemoattractant protein-1 and KC/GRO/melanoma growth-stimulating activity gene expression in mouse peritoneal macrophages.

Authors:  Y Ohmori; T A Hamilton
Journal:  J Immunol       Date:  1994-09-01       Impact factor: 5.422

5.  The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta.

Authors:  R T Gazzinelli; I P Oswald; S Hieny; S L James; A Sher
Journal:  Eur J Immunol       Date:  1992-10       Impact factor: 5.532

6.  Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro.

Authors:  F Plata; J Wietzerbin; F G Pons; E Falcoff; H Eisen
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

7.  Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro.

Authors:  G N Vespa; F Q Cunha; J S Silva
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  Release of nitric oxide during the experimental infection with Trypanosoma cruzi.

Authors:  P Petray; M E Rottenberg; S Grinstein; A Orn
Journal:  Parasite Immunol       Date:  1994-04       Impact factor: 2.280

9.  Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection.

Authors:  J S Silva; P J Morrissey; K H Grabstein; K M Mohler; D Anderson; S G Reed
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

10.  Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta).

Authors:  J S Silva; D R Twardzik; S G Reed
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  47 in total

1.  CXCR3 and its ligands participate in the host response to Bordetella bronchiseptica infection of the mouse respiratory tract but are not required for clearance of bacteria from the lung.

Authors:  Daniel P Widney; Yan Hu; Amy K Foreman-Wykert; Kim C Bui; Tam T Nguyen; Bao Lu; Craig Gerard; Jeff F Miller; Jeffrey B Smith
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Authors:  Silvia I Cazorla; Pablo D Becker; Fernanda M Frank; Thomas Ebensen; María J Sartori; Ricardo S Corral; Emilio L Malchiodi; Carlos A Guzmán
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

3.  The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; William A Kuziel; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction.

Authors:  G P Garlet; C R B Cardoso; A P Campanelli; B R Ferreira; M J Avila-Campos; F Q Cunha; J S Silva
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

5.  Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.

Authors:  Juliana A S Gomes; Lilian M G Bahia-Oliveira; Manoel Otávio C Rocha; Solange C U Busek; Mauro M Teixeira; João Santana Silva; Rodrigo Correa-Oliveira
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  TNF microsatellite alleles in Brazilian Chagasic patients.

Authors:  Viriato Campelo; Roberto O Dantas; Renata T Simões; Celso T Mendes-Junior; Sandra M B Sousa; Aguinaldo L Simões; Eduardo A Donadi
Journal:  Dig Dis Sci       Date:  2007-08-23       Impact factor: 3.199

7.  Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes.

Authors:  Fabiana S Machado; Janeusa T Souto; Marcos A Rossi; Lisia Esper; Herbert B Tanowitz; Julio Aliberti; João S Silva
Journal:  Microbes Infect       Date:  2008-10-08       Impact factor: 2.700

8.  Mexican Trypanosoma cruzi T. cruzi I strains with different degrees of virulence induce diverse humoral and cellular immune responses in a murine experimental infection model.

Authors:  B Espinoza; T Rico; S Sosa; E Oaxaca; A Vizcaino-Castillo; M L Caballero; I Martínez
Journal:  J Biomed Biotechnol       Date:  2010-04-11

9.  Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or Myd88-deficient mice.

Authors:  Ana-Carolina Oliveira; Bruna C de Alencar; Fanny Tzelepis; Weberton Klezewsky; Raquel N da Silva; Fabieni S Neves; Gisele S Cavalcanti; Silvia Boscardin; Marise P Nunes; Marcelo F Santiago; Alberto Nóbrega; Maurício M Rodrigues; Maria Bellio
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

10.  IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis.

Authors:  Paulo Marcos da Matta Guedes; Fredy R S Gutierrez; Flavia L Maia; Cristiane M Milanezi; Grace K Silva; Wander R Pavanelli; João S Silva
Journal:  PLoS Negl Trop Dis       Date:  2010-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.